Congress locks in NIH research funding, bars agency from killing grants for policy shifts
H.R. 4007 — PHARA Act of 2025 · Filed by Bonnie Watson Coleman (D-NJ) · 62 cosponsors · Introduced Jun 12, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires the NIH to immediately release and fully fund all existing grant agreements and pay pending reimbursement requests, while prohibiting the agency from terminating active research grants. Going forward, new NIH grants must include termination clauses that allow cancellation only for material breach, changed circumstances, or mutual agreement—with 90 days' notice and mandatory renegotiation attempts. The bill explicitly bars the NIH from terminating grants simply because they no longer align with agency priorities or program goals.
Why we flagged it
The bill's core function is to shield active NIH research grants from termination on grounds of changed agency priorities, ensuring continuity of federally funded scientific work. It is fundamentally a constraint on executive discretion in grant administration, not a new spending authorization.
What the text implies
- The bill may constrain the NIH Director's ability to reallocate resources in response to emerging public health crises or scientific breakthroughs that shift research priorities.
- By prohibiting termination for 'no longer effectuating program goals,' the bill could lock the agency into funding research that becomes scientifically obsolete or misaligned with evidence-based priorities.
The full analysis lists 4 implications of this text.
Who stands to gain
research institutions (universities, medical centers, non-profit research organizations); individual researchers and research teams with active NIH grants